Max Robotics — Global Service Robot Directory + US Certification

About

Paul Tempst is a distinguished biochemist and proteomics researcher whose work has fundamentally advanced our understanding of serum-based biomarker discovery and peptidase biology. His most celebrated contributions center on the development of serum peptidomics — the systematic profiling of proteolytically derived peptides in human blood — as a powerful tool for cancer diagnostics. His landmark 2004 paper on magnetic particle-assisted, automated sample processing coupled with MALDI-TOF mass spectrometry (449 citations) established a reproducible, high-throughput platform for serum peptide profiling that became a cornerstone methodology in clinical proteomics. Building on this foundation, Tempst demonstrated in 2006 (178 citations) that serum peptidome patterns could reliably distinguish metastatic thyroid carcinoma from healthy controls, independent of confounding variables like gender and age — a finding with significant translational implications. His 2007 introduction of the Sequence-Specific Exopeptidase Activity Test (SSEAT, 86 citations) further refined the field by enabling direct functional biomarker discovery through real-time enzyme activity profiling in complex biological matrices. Tempst's body of work has collectively shaped modern approaches to cancer biomarker research and established peptidase activity monitoring as an essential dimension of functional proteomics.